The antibody medicine helps in the early stages of the disease by clearing a protein that builds up in the brains of people with this type of dementia.
Although not a cure, charities say the results in the journal JAMA mark a new era where Alzheimer's can be treated. BBC News
See also:
- Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial JAMA
- Results from Lilly's Landmark Phase 3 Trial of Donanemab Presented at Alzheimer's Association Conference and Published in JAMA Eli Lilly
- “Another milestone” – successful phase 3 trial of alzheimer’s drug, donanemab, confirmed Alzheimer's Research UK
- New drug donanemab is 'a turning point in the fight against Alzheimer’s' Alzheimer's Society
- How does donanemab fight Alzheimer's? And when will it be approved in the UK and US? Everything you need to know about game-changing new drug The Daily Mail
- Are we REALLY at a 'turning point in the fight against Alzheimer's'? Breakthrough new drugs halt cruel disease's decline... but experts warn crippling side effects (and cost) may outweigh any benefits The Daily Mail
- What impact will Alzheimer's drug donanemab have? The Guardian
- Everything we know about breakthrough Alzheimer’s drug Donanemab The Independent
- Why is this Alzheimer’s breakthrough so important? The Independent
- Alzheimer’s drug: Breakthrough medication could be available on the NHS by 2025, experts say iNews
- Alzheimer’s drug donanemab helps most when taken at earliest disease stage, study finds Nature
- Donanemab found to slow Alzheimer's and hailed a 'turning point in fight against disease' Sky News
No comments:
Post a Comment